Solid Biosciences Inc. (SLDB)

Market Cap	60.73M
Revenue (ttm)	n/a
Net Income (ttm)	-90.83M
Shares Out	20.18M
EPS (ttm)	-4.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,267
Open	2.85
Previous Close	2.82
Day's Range	2.82 - 3.07
52-Week Range	1.81 - 8.20
Beta	1.33
Analysts	Buy
Price Target	5.00 (+66.11%)
Earnings Date	Nov 8, 2023

About SLDB

Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in dev...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2018
• Employees: 87
• Stock Exchange: NASDAQ
• Ticker Symbol: SLDB

Financial Performance

In 2022, SLDB's revenue was $8.09 million, a decrease of -40.57% compared to the previous year's $13.62 million. Losses were -$85.98 million, 19.1% more than in 2021.

Analyst Forecast

According to one analyst, the rating for SLDB stock is "Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(66.11% upside)

Analyst Consensus: Buy